Furthermore, morphological and immunohistochemical measurements demonstrated improvements, including reduction of inflammatory cell infiltration and vacuole formation in injured nerves and decreased expression of SP and IBA1 in spinal dorsal horns corresponding to BPA levels, indicating CWS as a potential therapy for reducing inflammation and pain at early stage of peripheral nerve injury. This evidence concerns the gene TFF2 and peripheral nerve injury.